Fig. 3.

Hypermutation in individual recurrence samples is associated with increased MGMT promoter methylation and reduced expression. (A) Hierarchical clustering by Ward’s minimum variance method of methylation levels at 27 CpG sites for individual recurrence samples labeled by patient ID number, presence or absence of hypermutation (HM), and subtype (A: astrocytoma, O: oligodendroglioma). (B) MGMT expression level by RNA log count for individual recurrence samples by presence of absence of hypermutation. (C) MGMT expression level by RNA log count and average methylation level at the MGMT promoter for each individual recurrence sample.